Phase 1 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who have signed the specific consent form for their group (cohort) in the trial
• People whose tumour has been tested for certain genetic markers/mutations using an approved, certified laboratory test, with full test results available — this includes blood-based testing done before or during the screening period (confirm with trial site for specific biomarker requirements)
• People who are reasonably active and able to carry out light daily activities, as measured by a standard performance scale (ECOG score of 0 or 1)
• People who are expected to live at least 3 months or more, as judged by the treating doctor
• People who have been diagnosed with bowel cancer (colon or rectal cancer) confirmed by laboratory tissue analysis, that has spread to other parts of the body (metastatic disease)
• People who have already received prior treatment for their metastatic disease
• People who have at least one measurable tumour that can be tracked using standard imaging criteria
• People who have adequate blood counts and organ function within 14 days before starting the study treatment
• People who are able to follow the study requirements, in the doctor's judgement
• Women who could become pregnant must agree to either avoid heterosexual intercourse or use contraception during the study
• Men must agree to either avoid intercourse or use contraception, and must agree not to donate sperm during the study
• People who are willing to provide a baseline tumour tissue sample for research purposes

Who may not be able to join:

• People who are currently enrolled and actively participating in another clinical trial that involves a treatment (those in the follow-up phase of a previous trial may still be considered)
• People who have received any systemic cancer treatment within 2 weeks, or within 5 half-lives of the drug (whichever is shorter), before starting the study treatment
• People who have received an experimental (investigational) treatment within 28 days before starting the study treatment
• People who are pregnant, breastfeeding, or planning to become pregnant during the study
• People with a serious medical condition or abnormal laboratory results that, in the doctor's opinion, would make participation unsafe or make it difficult to interpret the study results
• People who have had a severe infection in the 4 weeks before starting the study treatment, or who have an active infection that the doctor considers a safety risk
• People who have not fully recovered from a previous surgery in a way that could affect the safety or results of the study
• People with uncontrolled build-up of fluid around the lungs, heart, or abdomen that requires drainage more than once a month
• People with cancer-related pain that is not adequately controlled
• People with uncontrolled or symptomatic high calcium levels in the blood
• People with clinically significant active liver disease
• People with HIV, unless they have been stable on HIV treatment for at least 4 weeks, have adequate immune cell counts, have an undetectable viral load, and have not had a serious HIV-related infection in the past 12 months
• People with brain or central nervous system (CNS) metastases that are causing symptoms, have not been treated, or are actively getting worse
• People with a history of cancer spreading to the membranes surrounding the brain or spinal cord
• People who have had a different cancer (other than bowel cancer) within the past 2 years, unless that cancer carries a very low risk of spreading or causing death
• People with any other condition, unresolved side effects from previous treatment, or laboratory finding that would make use of the study drug unsafe or affect the results
• People who need to take a medication that is known to interact with or interfere with the study treatments

Important: Always verify eligibility with the trial site directly before applying.